A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.

A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots.
This event highlighted some of the AI, machine learning and data-driven technologies from across Imperial that are being used for applications ranging from wireless video transfer to electric vehicle charging infrastructure, planning new offshore windfarms and optimising drug development and production.
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
Imperial.Tech.Pitch: Transition to zero pollution saw researchers and inventors from Imperial showcase their technologies and innovations that are helping companies and sectors to transition to a zero pollution future.
Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington’s disease, viral conditions such as HIV, and cancers
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier.
Learn about our programme of events and sign up to be alerted for future events
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.